Mary Davis
Family · Victoria, VANPI 1588856629
Payments from drug & device makers
Across 230 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$590
- Lilly USA, LLC$553
- Pfizer$394
- Novartis$333
- Amgen$294
- Takeda Pharmaceuticals U.S.A., Inc.$239
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,25697%
- Education$1143%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $590 |
| Lilly USA, LLC | 31 | $553 |
| Pfizer | 23 | $394 |
| Novartis | 18 | $333 |
| Amgen | 18 | $294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $239 |
| Esperion Therapeutics, Inc. | 5 | $211 |
| Abbott | 9 | $186 |
| Actelion Pharmaceuticals US, Inc. | 5 | $180 |
| Bayer | 12 | $179 |
| Exact Sciences | 8 | $161 |
| AbbVie | 9 | $146 |
| AstraZeneca | 8 | $118 |
| Phathom Pharmaceuticals, Inc. | 5 | $96 |
| Boehringer Ingelheim | 6 | $95 |
| Dexcom, Inc. | 4 | $77 |
| Shield Therapeutics Inc | 2 | $71 |
| Radius Health, Inc. | 2 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Ardelyx, Inc. | 3 | $51 |
| GSK | 3 | $41 |
| Edwards Lifesciences | 2 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| CSL Behring | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Watermark Medical, Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,369 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 135 | $159,911 |
| MounjaroTirzepatide | 68 | $76,637 |
| JardianceEmpagliflozin | 97 | $67,918 |
| XareltoRivaroxaban | 63 | $66,119 |
| TrulicityDulaglutide | 50 | $65,734 |
| RybelsusSemaglutide | 45 | $52,358 |
| EliquisApixaban | 46 | $47,262 |
| JanuviaSitagliptin Phosphate | 73 | $46,495 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $36,435 |
| FarxigaDapagliflozin Propanediol | 31 | $33,210 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 35 | $32,759 |
| Repatha SureclickEvolocumab | 24 | $26,690 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 27 | $20,143 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $17,273 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $15,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $590 | $212,269180 claims |
| Lilly USA, LLCMounjaro, Trulicity | $553 | $142,371118 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $95 | $100,677132 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $41 | $58,03180 claims |
| PfizerEliquis | $394 | $47,26246 claims |
| AstraZenecaFarxiga, Symbicort, Daliresp | $118 | $45,54276 claims |
| AbbVieSynthroid | $146 | $3,27055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.
Other family in Victoria
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.